Earnings Preview: AstraZeneca braced for worst ever quarter
This article was originally published in Scrip
AstraZeneca is gearing up for its poorest quarterly revenue performance to date on 25 April. Also spicing up its AGM, to be held on the same day, is a likely revolt over pay.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.